|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
There is one clinical trial.
Prone positioning (PP) is an effective first-line intervention to treat moderate-severe acute respiratory distress syndrome (ARDS) patients receiving invasive mechanical ventilation, as it improves gas exchanges and lowers mortality.The use of PP in awake self-ventilating patients with (e.g. COVID-19 induced) ARDS could improve gas exchange and reduce the need for invasive mechanical ventilation, but has not been studied outside of case series.The investigators will conduct a randomized controlled study of patients with COVID-19 induced respiratory failure to determine if prone positioning reduces the need for mechanical ventilation compared to standard management.
Description: A measure of effect of awake prone positioning in reducing requirement for invasive mechanical ventilation.Measure: The effect of prone positioning on requirement for invasive mechanical ventilation in patients with COVID 19 induced respiratory failure. Time: Up to 28 days post randomisation
Description: Total time spent in prone and supine position as recorded by nurseMeasure: Length of time tolerating prone positioning Time: Daily during intervention up to 28 days post randomisation
Description: Measure of change in oxygenation before interventionMeasure: PaO2/FiO2 measured before prone positioning Time: Immediately before intervention
Description: Measure of change in oxygenation following interventionMeasure: PaO2/FiO2 ratio after 1 hours of prone positioning Time: During intervention
Description: Measure of change in oxygenation using pulse oximetry before intervention where ABG not availableMeasure: SpO2/FiO2 ratio measured before prone positioning Time: Immediately before intervention
Description: Measure of change in oxygenation before intervention where ABG not availableMeasure: SpO2/FiO2 ratio after 1 hours of prone positioning Time: During Intervention
Description: Escalation of ventilatory supportMeasure: Number requiring increase in ventilatory assistance (CPAP+BIPAP+IMV etc) Time: Up to 28 days post randomisation
Description: Measure of work of breathing in COVID-19 based on Oxygen Delivery Device, Oxygen Saturation and respiratory rate and accessory muscle use with 0-3 Mild, 4-6 Moderate and 7-10 SevereMeasure: Work of breathing assessment (Respiratory distress scale) Time: Immediately before and during intervention
Description: Substudy examining use of bioimpedance as a surrogate measure of lung edema following prone positioningMeasure: Changes in bioimpedance measures of lung edema in patients in PP Time: During intervention
Description: Rescue awake prone positioning in control patients in response to hypoxiaMeasure: Use of awake prone positioning as a rescue intervention in control patients Time: Up to 28 days post randomisation
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports